A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

Sponsors

Lead Sponsor: Swedish Orphan Biovitrum

Collaborator: PRA Health Sciences
Cytel Inc.
BioMérieux

Source Swedish Orphan Biovitrum
Brief Summary

Clinical study designed to collect blood for research purposes in patients after hematopoietic stem cell transplantation (HSCT) or in patients with a medical condition where the blood cells production is impaired. The blood samples will be used to study the role of Interferon gamma (IFNɣ) in graft failure or impairment of hematopoietic stem cell proliferation. The IFNɣ signature will be assessed by measuring primarily IFNɣ and C-X-C Motif Chemokine Ligand 9 (CXCL9).

Detailed Description

This clinical study is designed to investigate IFNγ activity in two cohorts of patients.

- First group will include patients post HSCT at risk of graft failure (GF) based on their underlying diseases and on the transplant procedure.

- Second group will contain patients with conditions where HSC proliferation is impaired (e.g. aplastic anemia) and with matched controls (healthy volunteers (HV) samples collected outside this clinical protocol).

IFNɣ activity will be assessed by measuring IFNγ and CXCL9 in serum.

For HSCT cohort, the following sampling time points are required: on day -7, pre HSCT on day 0, 1, 3, 5, 9, 13, 17, 21, 28, 31, 38 and one additional sample at the time when primary or secondary GF is suspected if not on the planned schedule. In addition, the following time points are recommended: day 7, 11, 15, 19, 24, 35, 42. It is also suggested to collect a sample when Graft vs Host Disease (GVHD) is diagnosed during any visit that the patients will attend as part of his/her standard treatment during the first 100 days post-transplant. The patient will be followed up until around day 100 post-transplant. This follow up will consist of capturing HSCT outcome information from patient hospital records around day 100.

For IHSCP cohort pre-transplant, it is recommended that, one sample per patient at the time of diagnosis (if possible not more than 1 week from the date of diagnosis) is collected. Age/sex matched control samples should be collected from healthy volunteers or patients with malignant disease outside of this protocol after appropriate consent.

Different sets of data will be collected for the HSCT and IHSCP cohorts respectively as described below:

Data collected for both cohorts

- Age and sex

- Inflammatory markers

- IFNɣ

- CXCL9

- Other potential relevant exploratory biomarkers

- Diagnosis

- Date of disease diagnosis

- Relevant medical history

- Date and time of sample collection

Data collected for HSCT cohort only

- Laboratory parameters assessed at the site laboratory on the date of sample collection and between collection dates when available:

- Absolute neutrophile count (ANC) and Platelets will be measured as per the schedule of assessment, if possible when routine monitoring of patient health is conducted

- Ferritin and Chimerism data will be collected when available (if measured as per site routine practice)

- Concomitant medications at the time of sample collection and between collection dates

- Presence of infection at the time of sample collection with the date of onset

- Presence of donor specific antibodies (DSA)

- Transplant information

- Date of start of conditioning

- Type of conditioning (Reduced Intensity Conditioning (RIC) / Myeloablative Conditioning (MAC) / Non-myeloablative Conditioning (NMAC) and medications

- Transplant details (donor type, degree of match, transplant manipulation, stem cell source)

- Date of transplant

- Date of primary / secondary GF or of confirmed engraftment

- GVHD with the date of onset

- Post-transplant treatment and date (Donor Lymphocyte Infusion (DLI), Stem Cell (SC) boost, growth factor, GVHD prophylaxis, second HSCT procedure)

Data collected for IHSCP cohort only

- Disease severity

- In addition, the following data will be recorded for pediatric patients up to 18 years old, if available:

- PNH clones

- History of hepatitis

- Karyotype

Study duration:

The study will be conducted, until the required number of patients is recruited.

- HSCT cohort: At patient level, the study will last about 100 days from pre-transplant blood collection to last follow up data collection around day 100 post HSCT, matching the standard HSCT patient care

- IHSCP cohort: At patient level the study will last 1 day.

Overall Status Not yet recruiting
Start Date July 2020
Completion Date December 31, 2021
Primary Completion Date December 31, 2021
Study Type Observational
Primary Outcome
Measure Time Frame
HSCT cohort: IFNγ signature pre-and post-transplant day (-7) to day 100
HSCT cohort: Relationship between IFNγ and the risk of graft failure day (-7) to day 100
HSCT cohort: Relationship between IFNγ and the occurrence of GVHD day (-7) to day 100
IHSCP cohort: IFNγ signature pre-transplant day of sample collection (1 time point)
Enrollment 200
Condition
Intervention

Intervention Type: Procedure

Intervention Name: blood collection

Description: Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.

Eligibility

Sampling Method: Probability Sample

Criteria:

Inclusion Criteria:

- The patient must have consented to the use of their clinical data and biological samples for research investigations.

- In HSCT cohort:

- Patients with underlying:

i. non-malignant hematological disease (e.g. autoimmune and metabolic disorders, aplastic anemia, Sickle cell anemia, Fanconi anemia, Diamond-blackfan anemia, thalassemia, osteopetrosis, Wiskott-Aldrich syndrome, severe combined immunodeficiency) or ii. malignant disease with higher risk of GF, i.e. Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) with primary induction failure, second partial remission or relapse; Chronic Myeloid Leukemia (CML) in blastic phase (circulating blast or blast above 5% in biopsy); Non Hodgkin and Hodgkin Lymphoma and multiple myeloma with primary induction failure, second partial remission or relapse, myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) with splenomegaly, myelofibrosis with portal hypertension pre-transplant, MDS/MPD overlap syndromes

- and who received allogeneic HSCT and are at higher risk of graft failure based on at least one of the following criteria: i. Having received reduced intensity conditioning (RIC) or non myeloablative conditioning (NMA) combined with a non-malignant disease or having received graft from Bone Marrow (BM) ii. Ex vivo T cell depleted graft iii. Graft from mismatched unrelated donor or haploidentical donor iv. Graft from Umbilical Cord Blood (UCB)

- In the IHSCP cohort:

- Patients with IHSCP pre-transplant (e.g. aplastic anemia)

Exclusion Criteria:

- HLH patients

- Body weight < 10kg

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

Overall Contact

Last Name: Emmanuel Monnet, PhD

Phone: +41 79 650 06 08

Email: [email protected]

Verification Date

July 2020

Responsible Party

Type: Sponsor

Has Expanded Access No
Arm Group

Label: HSCT - Hematopoetic Stem Cell Proliferation

Description: Patients who received hematopoietic stem cell transplant

Label: IHSCP - Impaired HSC proliferation

Description: Patients with impaired hematopoietic stem cell proliferation

Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

Source: ClinicalTrials.gov